Global Custom Market Research Reports Provider Company

phone

Ignyta Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 23 Oct 2018
  • Number of Pages: 51
  • Category: Company Profile
  • Country: United States of America
Summary

Ignyta Inc (Ignyta), formerly NexDx Inc, a subsidiary of F. Hoffmann-La Roche Ltd, is a cancer care service provider. The company discovers, develops and commercializes new drugs targeting activated genes in cancer cells. It develops products using integrated therapeutic technology (Rx/Dx). Ignytas pipeline products include entrectinib, RXDX-105, taladegib and RXDX-106. The companys entrectinib product is designed to target cancers harboring activating molecular alterations. Its RXDX-106 is a novel small molecule immunomodulatory agent with potent anti-tumor activity. Ignyta offers clinical trials and research and development services. The company serves cancer patients and pharmaceuticals industries. Ignytais headquartered in San Diego, California, the US.

Ignyta Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData


List of Tables 4
List of Figures 4
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ignyta Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Ignyta Acquires Four Oncology R&D Assets from Cephalon 11
Venture Financing 13
NexDx Raises US$5.5 Million In Series B Financing 13
Partnerships 14
Ignyta and Institut Curie Enter into Partnership 14
Ignyta Enters into Research Agreement with Moffitt Cancer Center 15
Merger 16
Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction 16
Licensing Agreements 17
Ignyta Amends Licensing Agreement with Eli Lilly 17
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 19
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 21
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for Tyrosine Kinase Inhibitors 22
Equity Offering 24
Ignyta Prices Public Offering of Shares for USD160 Million 24
Ignyta Raises USD88.4 Million in Public Offering of Shares 26
Ignyta Raises USD57.5 Million in Public Offering of Shares 28
Ignyta Raises USD30 Million in Private Placement of Shares 30
Ignyta Raises USD75 Million in Public Offering of Shares 31
Ignyta Raises USD42 Million in Private Placement of Shares 33
Ignyta Completes Public Offering Of Shares For US$55.2 Million 34
Ignyta Completes Private Placement Of Shares For US$7.8 Million 36
Ignyta Completes Private Placement Of Shares For US$46.2 Million 37
Acquisition 38
Roche Acquires Ignyta for USD1.7 Billion 38
Ignyta Acquires Actagene Oncology 40
Ignyta Inc - Key Competitors 41
Ignyta Inc - Locations And Subsidiaries 42
Head Office 42
Recent Developments 43
Financial Announcements 43
Nov 07, 2017: Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results 43
Aug 08, 2017: Ignyta Announces Second Quarter 2017 Company Highlights and Financial Results 45
May 01, 2017: Ignyta Announces First Quarter 2017 Company Highlights and Financial Results 47
Mar 14, 2017: Ignyta Announces Full Year 2016 Company Highlights and Financial Results 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List Of Tables


Ignyta Inc, Pharmaceuticals & Healthcare, Key Facts 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ignyta Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ignyta Acquires Four Oncology R&D Assets from Cephalon 11
NexDx Raises US$5.5 Million In Series B Financing 13
Ignyta and Institut Curie Enter into Partnership 14
Ignyta Enters into Research Agreement with Moffitt Cancer Center 15
Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction 16
Ignyta Amends Licensing Agreement with Eli Lilly 17
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 19
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 21
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for Tyrosine Kinase Inhibitors 22
Ignyta Prices Public Offering of Shares for USD160 Million 24
Ignyta Raises USD88.4 Million in Public Offering of Shares 26
Ignyta Raises USD57.5 Million in Public Offering of Shares 28
Ignyta Raises USD30 Million in Private Placement of Shares 30
Ignyta Raises USD75 Million in Public Offering of Shares 31
Ignyta Raises USD42 Million in Private Placement of Shares 33
Ignyta Completes Public Offering Of Shares For US$55.2 Million 34
Ignyta Completes Private Placement Of Shares For US$7.8 Million 36
Ignyta Completes Private Placement Of Shares For US$46.2 Million 37
Roche Acquires Ignyta for USD1.7 Billion 38
Ignyta Acquires Actagene Oncology 40
Ignyta Inc, Key Competitors 41

List Of Figures


Ignyta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ignyta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018 9

Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution;

View Report

UDG Healthcare plc (UDG) formerly, United Drug plc is a provider of outsourced commercial solutions to healthcare companies. It offers supply chain, packaging, sales and marketing, medical and regulatory services

View Report

Oxurion NV(Oxurion) formerly known as ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The companys ocriplasmin, a recombinant derivative of the plasmin protein, is

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports